- The U.S. FDA approved Ionis Pharmaceuticals' Zanvastro as the first treatment for Alexander disease based on clinical study data showing improved patient stability.
- Pfizer and Medicus Pharma entered a co-development agreement for an antibody drug conjugate targeting CD228, with Medicus paying $12 million upfront and Pfizer funding development.
- Typewriter Therapeutics emerged from stealth mode with $56 million in Series A funding, while Tscan Therapeutics announced plans to reduce its workforce by 75% amid strategic reorganization.
